Home LiteratureArticle Details
PMID: 41362608 Published · epublish English Journal Article

Proteomics- and BRET- screens identify SPRY2 as a Ras effector that impacts its membrane organization.

iScience ·Vol. 28 ·No. 12 ·2025-12-19 ·页码 113974

Pavic K, Hood FE, Duval CJ, Manoharan GB, Laurini C, Siddiqui FA, Mo SPL, Prior IA, Abankwa DK

Abstract

Few regulators of K-Ras plasma membrane organization are known. We combined TurboID-based proximity proteomics with a BRET screen to identify eight potential K-Ras G-domain interactors. We focused on APLP2, which indirectly engages with C-Raf in immediate proximity to K-Ras, and SPRY2, which exhibits properties of an effector. Co-immunoprecipitation and BRET assays revealed that the SPRY2 C-terminal half binds oncogenic RasG12V more than full-length SPRY2. Both forms localize to the plasma membrane, but this localization and binding to K-Ras are disrupted by inhibitors of K-Ras membrane anchorage or activity. Mutations at the predicted interface of K-Ras and SPRY2's C-terminal region affect the interaction. Both full-length SPRY2 and its C-terminal fragment promote the differentiation of C2C12 muscle cells, a process requiring MAPK pathway inhibition. Finally, SPRY2 homo- and hetero-oligomerizes with SPRY4. We propose that active K-Ras recruits SPRY2 dimers to the membrane, where they block Ras effector access.

Keywords
Membrane architecture Molecular biology Proteomics
作者与单位
共 9 位作者,点击展开单位 / ORCID
Pavic Karolina
Cancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, University of Luxembourg, 4362 Esch-sur-Alzette, Luxembourg.
Hood Fiona Elizabeth
Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 3BX, UK.
Duval Carla Jane
Cancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, University of Luxembourg, 4362 Esch-sur-Alzette, Luxembourg.
Manoharan Ganesh Babu
Cancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, University of Luxembourg, 4362 Esch-sur-Alzette, Luxembourg.
Laurini Christina
Cancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, University of Luxembourg, 4362 Esch-sur-Alzette, Luxembourg.
Siddiqui Farid Ahmad
Institute of Biomedicine, University of Turku, 20520 Turku, Finland.
Mo Stephanie Puy Lam
Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 3BX, UK.
Prior Ian Andrew
Department of Molecular and Clinical Cancer Medicine, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool L69 3BX, UK.
Abankwa Daniel Kwaku
Cancer Cell Biology and Drug Discovery Group, Department of Life Sciences and Medicine, University of Luxembourg, 4362 Esch-sur-Alzette, Luxembourg.
Article Info
Journal
iScience
Abbr.
iScience
ISSN
2589-0042
Published
2025-12-19
电子出版
2025-00-07
页码
113974
Language
English
Country/Region
United States
NLM ID
101724038
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com